A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy
Stopped early · Phase 2 · Has a placebo group
Conditions studied: Epilepsy
In brief
The purpose of this study is to evaluate the efficacy, safety and tolerability of VX-765 in subjects with treatment-resistant partial epilepsy.
Key facts
- Study ID
- NCT01501383
- Run by
- Vertex Pharmaceuticals Incorporated
- People needed
- 55
- Starts
- 2011-12-01
- Last updated by the study team
- 2020-09-30
Who can join
Age: 18 and older, up to 64. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Alabama — Northport, Alabama, United States
- Arizona — Phoenix, Arizona, United States
- Arizon — Phoenix, Arizona, United States
- Arkansas — Little Rock, Arkansas, United States
- California — Loma Linda, California, United States
- Florida — Bradenton, Florida, United States
- Florida — Wellington, Florida, United States
- Idaho — Boise, Idaho, United States
- Maryland — Baltimore, Maryland, United States
- Michigan — Farmington Hills, Michigan, United States
- Minnesota — Saint Paul, Minnesota, United States
- New York — New York, New York, United States
- New York — The Bronx, New York, United States
- North Carolina — Asheville, North Carolina, United States
- North Carolina — Charlotte, North Carolina, United States
- Ohio — Columbus, Ohio, United States
- Oklahoma — Oklahoma City, Oklahoma, United States
- Pennsylvania — Philadelphia, Pennsylvania, United States
- Texas — Dallas, Texas, United States
- Utah — Orem, Utah, United States
- Virginia — Charlottesville, Virginia, United States
- Washington — Renton, Washington, United States
- Germany — Bonn, Germany
- Germany — Kork, Germany
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.